CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Mayo Clinic
National Cancer Institute, Egypt
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Changzhou No.2 People's Hospital
Jazz Pharmaceuticals
Yale University
M.D. Anderson Cancer Center
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Hangzhou Cancer Hospital
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Bayer
M.D. Anderson Cancer Center
University of California, Irvine
Fudan University
Peking University Cancer Hospital & Institute
Gilead Sciences
University of Manitoba
AntiCancer Research Jamaica
Hebei Medical University Fourth Hospital
Virogen Biotechnology Inc.
Ohio State University Comprehensive Cancer Center
Groupe Oncologie Radiotherapie Tete et Cou
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Sichuan University
National Cancer Institute (NCI)
National Taiwan University Hospital
National Cancer Institute (NCI)
Guangdong Provincial People's Hospital
University of Alabama at Birmingham
National Cancer Centre, Singapore
Virogin Biotech Ltd.
National Cancer Institute, Naples
Eye & ENT Hospital of Fudan University
Odense University Hospital
Case Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
Case Comprehensive Cancer Center
Washington University School of Medicine
Washington University School of Medicine
Tianjin Medical University Cancer Institute and Hospital
West China Hospital
Fred Hutchinson Cancer Center